Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Role of IRAK4 and IRF3 in the control of intracellular infection with Chlamydia pneumoniae.

Trumstedt C, Eriksson E, Lundberg AM, Yang TB, Yan ZQ, Wigzell H, Rottenberg ME.

J Leukoc Biol. 2007 Jun;81(6):1591-8. Epub 2007 Mar 14.

PMID:
17360955
3.

Induction of iNOS by Chlamydophila pneumoniae requires MyD88-dependent activation of JNK.

Rodriguez N, Lang R, Wantia N, Cirl C, Ertl T, Dürr S, Wagner H, Miethke T.

J Leukoc Biol. 2008 Dec;84(6):1585-93. doi: 10.1189/jlb.0508304. Epub 2008 Sep 17.

PMID:
18799752
4.

IFN-alpha beta-dependent, IFN-gamma secretion by bone marrow-derived macrophages controls an intracellular bacterial infection.

Rothfuchs AG, Gigliotti D, Palmblad K, Andersson U, Wigzell H, Rottenberg ME.

J Immunol. 2001 Dec 1;167(11):6453-61.

5.

Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.

Jiang Z, Mak TW, Sen G, Li X.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3533-8. Epub 2004 Feb 24.

6.

TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA.

Konno H, Yamamoto T, Yamazaki K, Gohda J, Akiyama T, Semba K, Goto H, Kato A, Yujiri T, Imai T, Kawaguchi Y, Su B, Takeuchi O, Akira S, Tsunetsugu-Yokota Y, Inoue J.

PLoS One. 2009 May 25;4(5):e5674. doi: 10.1371/journal.pone.0005674.

7.

Essential role of mitochondrial antiviral signaling, IFN regulatory factor (IRF)3, and IRF7 in Chlamydophila pneumoniae-mediated IFN-beta response and control of bacterial replication in human endothelial cells.

Buss C, Opitz B, Hocke AC, Lippmann J, van Laak V, Hippenstiel S, Krüll M, Suttorp N, Eitel J.

J Immunol. 2010 Mar 15;184(6):3072-8. doi: 10.4049/jimmunol.0902947. Epub 2010 Feb 12.

8.

IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism.

Stockinger S, Reutterer B, Schaljo B, Schellack C, Brunner S, Materna T, Yamamoto M, Akira S, Taniguchi T, Murray PJ, Müller M, Decker T.

J Immunol. 2004 Dec 15;173(12):7416-25.

9.

IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.

Sirén J, Pirhonen J, Julkunen I, Matikainen S.

J Immunol. 2005 Feb 15;174(4):1932-7.

10.

STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells.

Rothfuchs AG, Trumstedt C, Mattei F, Schiavoni G, Hidmark A, Wigzell H, Rottenberg ME.

J Immunol. 2006 Jun 1;176(11):6982-90.

11.

IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways.

Zhao J, Kong HJ, Li H, Huang B, Yang M, Zhu C, Bogunovic M, Zheng F, Mayer L, Ozato K, Unkeless J, Xiong H.

J Biol Chem. 2006 Apr 14;281(15):10073-80. Epub 2006 Feb 16.

12.

poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages.

Reimer T, Brcic M, Schweizer M, Jungi TW.

J Leukoc Biol. 2008 May;83(5):1249-57. doi: 10.1189/jlb.0607412. Epub 2008 Feb 5.

PMID:
18252870
14.

IRAK4 in TLR/IL-1R signaling: possible clinical applications.

Li X.

Eur J Immunol. 2008 Mar;38(3):614-8. doi: 10.1002/eji.200838161.

15.

Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells.

Osterlund P, Veckman V, Sirén J, Klucher KM, Hiscott J, Matikainen S, Julkunen I.

J Virol. 2005 Aug;79(15):9608-17.

17.
18.

Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways.

Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J.

J Virol. 2009 Jul;83(13):6757-68. doi: 10.1128/JVI.02570-08. Epub 2009 Apr 15.

20.

Viral activation of macrophages through TLR-dependent and -independent pathways.

Malmgaard L, Melchjorsen J, Bowie AG, Mogensen SC, Paludan SR.

J Immunol. 2004 Dec 1;173(11):6890-8.

Supplemental Content

Support Center